RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:37:42·⟳ 抓取 21:00:56 +23m14s·⚡ 决策 09-14 21:09:16 +8m20s·43.1 天前
Organon（OGN.US）无激素铜质宫内节育器 MIUDELLA 延长使用期至6年的 sNDA 获 FDA 受理审评，PDUFA 目标为2027年二季度
状态迁移仅为「申报→受理」，受理是 FDA 对申请材料完整性的程序性确认而非批准；PDUFA 行动日在2027年二季度（约7-9个月后），MIUDELLA 要到2026年末才上市、当前贡献为零收入，且 Organon 仅为2026年6月才从非上市的 Sebela 获得许可、经济条款未披露。事件在可交易窗口（1-10个交易日）内不改变收入、利润、订单或指引，方向虽轻微正面但无任何近期 edge，无论盘前价格如何反应均不构成正期望交易。
📄 原文RTTNews Biotech↗ 原文
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Organon & Co.（OGN.US）
sNDA 获受理是程序性节点而非批准，PDUFA 在2027年二季度（约7-9个月后）；MIUDELLA 2026年末才上市、当前零收入，Organon 仅为2026年6月从非上市 Sebela 许可权益、经济条款未披露；1-10个交易日内无收入/利润/指引增量，方向轻微正面但无 edge，不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
MIUDELLA 6年期 sNDA 获 FDA 受理只是程序性里程碑：批准要等到2027年二季度、产品2026年末才上市且当前零收入、许可经济条款未披露，对 Organon 近期业绩无增量，回避。
🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 low ↗
关键理由
- 受理不等于获批，PDUFA 在约7-9个月后的2027年二季度，短线无确定性兑现节点
- MIUDELLA 尚未商业化（预计2026年末上市），Organon 又只是许可方且分成条款未披露，无法量化相对其营收/市值的弹性
主要风险
- 若公司同日披露超预期的商业预付/放量准备或上调女性健康板块指引，可能改变 materiality 判断（本报道未包含此类信息）
- 两年后 FOMC 决议带来的宏观波动可能主导股价，与该个股催化无关，进一步削弱事件驱动纯度
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
未调用内部库：产品尚未上市、受理无销售指引含义，不存在可在近期窗口兑现的收入弹性；许可系2026年6月完成、条款未公开，做多缺乏量级基础
检索:MIUDELLA Organon 商业价值 许可条款 Sebela 销售峰值 女性健康业务占比 - 做多前查反向 · 来源 web · 影响 none
未额外检索反证：决策基于事件自身的非实质性与远时点，不依赖公司层面利空；宏观上两天后有 FOMC，事件驱动纯度更低
检索:Organon OGN 近期利空 法务 节育器 专利 债务 下调
先例如何影响了这次决策
对本次决策的影响:先例维度未提供可交易理由，与阶段/权益/量级分析一致，确认 AVOID；无需为 AVOID 结论补造先例面板
方向:未跑事件先例统计：FDA 受理 sNDA 属于例行程序性节点，经验上此类「受理」本身通常不驱动股价，真正波动锚点是 AdCom/PDUFA 批准或 CRL
涨幅量级:不足以用先例校准幅度，且本决策不依赖幅度——零收入、未上市产品在7-9个月后的审评结果对1-10日窗口无传导路径
形态:生物医药监管经验明确：『受理不是获批』，申报→受理阶段不构成风险消除或商业验证
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 48 ms
{"result": "search_processed_events:agent query=`organon miudella snda accepted fda six years | organon ogn copper iud miudella supplemental nda pdufa 2027 | sebela miudella license organon duration extension`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据 - fetch_decision_experience 成功 stock_tools HTTP · 25 ms
{
原文全文
展开原文 · 9,434 字
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
By
RTTNews Staff Writer
✉
Published:
9/14/2026 8:37 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Organon (
OGN
) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MIUDELLA, a hormone-free copper intrauterine device (IUD), seeking to extend its approved duration of use from three to six years.
The FDA's Prescription Drug User Fee Act (PDUFA) action is expected in the second quarter of 2027.
MIUDELLA is currently approved in the U.S. for prevention of pregnancy in females of reproductive potential for up to three years and is anticipated to become commercially available in late 2026.
The product was investigated in three U.S. clinical trials involving 1,904 women aged 17 to 45 years.
In the Phase 3 efficacy cohort of women aged 17 to 35 years, MIUDELLA demonstrated a first-year Pearl Index of 0.94 and a cumulative three-year Pearl Index of 1.05, corresponding to approximately 99% contraceptive effectiveness.
MIUDELLA Clinical Profile
The pivotal Phase 3 study was a prospective, multicenter, single-arm, open-label trial conducted across 42 U.S. centers. The primary endpoint evaluated contraceptive efficacy through three years using the Pearl Index.
The overall placement success rate was approximately 99%.
The most common adverse reactions reported in clinical trials included heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage and dyspareunia.
Discontinuation due to bleeding or pain adverse events declined from 8.5% in the first year to 3.2% by year three, while expulsion rates declined from 1.9% in year one to 0.9% in year three.
Organon-Sebela Agreement
Organon completed an agreement in June 2026 to exclusively license global rights to MIUDELLA from Sebela Women's Health.
If approved for six years of use, the expanded duration could broaden MIUDELLA's contraceptive positioning and provide women with a longer-term, hormone-free option.
MIUDELLA is currently subject to a Risk Evaluation and Mitigation Strategy (REMS), requiring healthcare providers to complete certification and training on proper insertion before using the device.
Near-term Catalyst
The key upcoming catalyst for Organon is the FDA's regulatory decision on the MIUDELLA sNDA, with PDUFA action expected in Q2 2027.
FDA approval
of the six-year indication would extend the duration of use for the hormone-free IUD and potentially strengthen Organon's women's
health
portfolio as MIUDELLA enters the U.S. commercial market.
OGN has traded between $5.69 and $13.78 over the past year. The stock closed Friday's trading (September 11, 2026) at $13.64, up 0.07%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
By
RTTNews Staff Writer
✉
Published:
9/14/2026 8:37 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Organon (
OGN
) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MIUDELLA, a hormone-free copper intrauterine device (IUD), seeking to extend its approved duration of use from three to six years.
The FDA's Prescription Drug User Fee Act (PDUFA) action is expected in the second quarter of 2027.
MIUDELLA is currently approved in the U.S. for prevention of pregnancy in females of reproductive potential for up to three years and is anticipated to become commercially available in late 2026.
The product was investigated in three U.S. clinical trials involving 1,904 women aged 17 to 45 years.
In the Phase 3 efficacy cohort of women aged 17 to 35 years, MIUDELLA demonstrated a first-year Pearl Index of 0.94 and a cumulative three-year Pearl Index of 1.05, corresponding to approximately 99% contraceptive effectiveness.
MIUDELLA Clinical Profile
The pivotal Phase 3 study was a prospective, multicenter, single-arm, open-label trial conducted across 42 U.S. centers. The primary endpoint evaluated contraceptive efficacy through three years using the Pearl Index.
The overall placement success rate was approximately 99%.
The most common adverse reactions reported in clinical trials included heavy menstrual bleeding, dysmenorrhea, intermenstrual bleeding, pelvic discomfort, procedural pain, pelvic pain, post-procedural hemorrhage and dyspareunia.
Discontinuation due to bleeding or pain adverse events declined from 8.5% in the first year to 3.2% by year three, while expulsion rates declined from 1.9% in year one to 0.9% in year three.
Organon-Sebela Agreement
Organon completed an agreement in June 2026 to exclusively license global rights to MIUDELLA from Sebela Women's Health.
If approved for six years of use, the expanded duration could broaden MIUDELLA's contraceptive positioning and provide women with a longer-term, hormone-free option.
MIUDELLA is currently subject to a Risk Evaluation and Mitigation Strategy (REMS), requiring healthcare providers to complete certification and training on proper insertion before using the device.
Near-term Catalyst
The key upcoming catalyst for Organon is the FDA's regulatory decision on the MIUDELLA sNDA, with PDUFA action expected in Q2 2027.
FDA approval
of the six-year indication would extend the duration of use for the hormone-free IUD and potentially strengthen Organon's women's
health
portfolio as MIUDELLA enters the U.S. commercial market.
OGN has traded between $5.69 and $13.78 over the past year. The stock closed Friday's trading (September 11, 2026) at $13.64, up 0.07%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
Organon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。